Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ: MXCT )

3.180 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,912
Open 3.180
Bid (Size) 2.550 (1)
Ask (Size) 3.330 (7)
Prev. Close 3.180
Today's Range 3.180 - 3.180
52wk Range 2.760 - 5.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill

Performance

YTD
-23.37%
-23.37%
1 Month
-27.06%
-27.06%
3 Month
-28.22%
-28.22%
6 Month
-18.67%
-18.67%
1 Year
-20.10%
-20.10%

More News

Read More
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
From Glancy Prongay & Murray LLP
Via Business Wire
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
MarketBeat Week in Review – 01/20 - 01/24
Via MarketBeat
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
Via MarketBeat
Exposures Product Safety
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
From MaxCyte, Inc
Via GlobeNewswire
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
From MaxCyte, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.